2 hrs ago
Approved Stem Cell Therapy Enters Knee Care in Tamil Nadu
Knee osteoarthritis can cause pain, stiffness and difficulty moving.
Some people with advanced disease may need knee replacement surgery.
Doctors at Kamakshi Memorial Hospitals in Chennai are offering another option for carefully selected patients with less advanced disease.
The treatment uses special cells taken from bone marrow from a donor.
The cells are intended to reduce inflammation and help protect cartilage.
The therapy has been approved by the Drugs Controller General of India, according to the release.
It is made by Stempeutics Research and supplied by Cipla.
Doctors say each patient must be assessed individually, and the treatment is not a replacement for surgery when surgery is needed.
Kamakshi Memorial Hospitals in Chennai has introduced an approved allogeneic bone marrow-derived mesenchymal stem cell therapy for selected knee osteoarthritis patients.
The treatment is intended for patients with mild to moderate, including Grade II and III, knee osteoarthritis as a potential knee-preservation option.
The therapy received approval from the Drugs Controller General of India, according to the press release.
Stempeutics Research manufactures the therapy, which is made available by Cipla.
Doctors emphasized that treatment decisions should depend on disease severity, individual condition and clinical assessment, while knee replacement remains established for advanced osteoarthritis.
- Who
- Dr. Deepak Kumar KS and Dr. Sathish Kumar Thangamani, working with Kamakshi Memorial Hospitals, administered the therapy to carefully selected patients.
- What
- An approved allogeneic bone marrow-derived mesenchymal stem cell therapy for knee osteoarthritis entered clinical practice in Tamil Nadu.
- Where
- Dr. Kamakshi Memorial Hospitals in Chennai, Tamil Nadu, India.
- When
- September 10, according to the article; the year is not specified.
- Why
- The therapy is being offered as a potential knee-preservation option for selected patients with mild to moderate osteoarthritis, with the aim of delaying or avoiding replacement surgery where clinically appropriate.
Key facts
- Condition
- Knee osteoarthritis
- Treatment
- Allogeneic bone marrow-derived mesenchymal stem cell therapy
- Approval
- Approved by the Drugs Controller General of India, according to the press release
- Eligible disease stages
- The release identifies Grade II and III knee osteoarthritis as potential stages for treatment
- Manufacturer
- Stempeutics Research
- Availability
- Cipla
- Hospital
- Kamakshi Memorial Hospitals, Chennai
Quotes
Dr. Sathish Kumar Thangamani
Senior assistant professor at Stanley Medical College and consultant at Kamakshi Memorial Hospitals
“As knee replacement specialists, we should not look at replacement as the first and only solution. Wherever clinically appropriate, I believe in exploring every possible avenue to preserve the patient’s natural knee. We are constantly looking at newer, scientifically supported treatment options that can potentially help patients maintain their joint and quality of life”
theprint.in
“The collaboration marks an important step in translating advances in regenerative medicine into clinical practice. We hope this approach will ultimately benefit many patients with knee osteoarthritis.”
theprint.in
Sources
Related news
Raising awareness on avascular necrosis: early detection saves hip
Safdarjung Hospital Performs First Robot-Assisted Total Knee Replacement
SRV Hospitals Launches Robotic-Assisted Joint Replacement Centre In Chembur
Madhu Chopra Shares X-Ray After Successful Knee Replacement
Robotic Joint Replacement Gains Momentum Across India
Kartik Aaryan’s Knee Surgery Raises Questions About Injury Treatment
Andhra Pradesh Seeks Curbs on Ethanol Sanitiser Sales
New Drugs Bill Proposes Renaming DCGI, Medical Devices Under Law
UPSC Weekly Concepts Snapshot: Dengue Vaccine, Tax Test, and POPs Explained
India Approves First Dengue Vaccine
